Innovative Silk Protein Science to Improve Ocular Health

SILKTECH focuses on innovating and developing silk-derived protein (SDP) products for ophthalmic applications. The company’s patented SDP material is currently being developed as a novel compound for the treatment of patients with dry eye disease. SILKTECH is based in Plymouth, MN and is financially backed by a combination of angels, grants and recently from a financing round by Skyview Ventures LLC.

“SILKTECH’s SDP-4 represents an exciting and potentially disruptive treatment approach to several, common ocular surface disorders, including dry eye.” — Emmett T. Cunningham, Jr, MD, PhD, MPH, an internationally recognized ocular inflammatory disease expert 

“The field of protein-based treatments for dry eye is significant and could represent one of the key mechanisms to managing this vast disease. SDP-4 is a prime example of how this silk protein may affect lubrication, inflammation and ocular surface healing.” — Paul Karpecki, OD, a leading expert in the field of dry eye disease